The Translational Genomics Research Institute (TGen), a proud division of City of Hope, has unveiled a groundbreaking advancement in the field of precision oncology with the launch of JAYseq™, a clinical whole-genome sequencing test tailored specifically for multiple myeloma. This cancer, known for ravaging plasma cells responsible for antibody production, ranks as the second most diagnosed blood cancer in the United States, with approximately 35,000 new patients annually. JAYseq promises to revolutionize the diagnostic landscape by delivering a comprehensive genomic profile that can enable personalized treatment strategies within a remarkably short 72-hour window.
Unlike conventional diagnostic approaches, which often rely on time-consuming and sequential methods such as fluorescence in situ hybridization (FISH) or cytogenetics that examine limited genomic regions, JAYseq offers researchers and clinicians an unparalleled opportunity to analyze the entirety of a patient’s DNA. This includes all three billion base pairs, thus furnishing a holistic molecular map of the tumor’s genetic landscape. Importantly, this breadth of analysis enables the detection of an array of genetic alterations — from small mutations and insertions-deletions to copy number variations, complex rearrangements, and chromosomal translocations — all crucial for tailoring effective therapeutic interventions.
The complexity of multiple myeloma’s genomic architecture has historically posed significant challenges for diagnostic precision, primarily due to the difficulty in isolating malignant plasma cells from the surrounding bone marrow milieu. Addressing this obstacle, JAYseq employs an advanced magnetic cell sorting technique that targets CD138+ cells, which are markers specific to malignant plasma cells. This precision enrichment, paired with high-throughput sequencing technology, elevates the sensitivity and accuracy of detecting pathogenic mutations and structural variations, ensuring that no key driver mutations evade detection.
Central to JAYseq’s rapid turnaround is the proprietary ALTseq™ platform developed by TGen Clinical Laboratory, a CAP-accredited facility with a proven track record in genomics diagnostics. This state-of-the-art sequencing technology supports the simultaneous and comprehensive interrogation of cancer genomes, accelerating the diagnostic timeline that has traditionally hindered swift clinical decision-making. The ability to provide actionable genomic data in under 72 hours is particularly vital for multiple myeloma patients, where early therapeutic intervention can profoundly influence prognosis and survival outcomes.
Dr. Jeffrey M. Trent, TGen’s President and Research Director, emphasizes the paradigm shift that JAYseq heralds in oncology testing. By leveraging whole-genome sequencing at unprecedented speeds, clinicians are empowered to navigate the intricate genomic heterogeneity of multiple myeloma, making precise treatment decisions backed by a detailed understanding of the tumor’s molecular drivers. This innovation marks a substantial leap from prior methodologies, spotlighting the essential role of genomics in fostering individualized medicine.
Among the key clinical advantages of JAYseq is its capacity to detect biomarkers associated with high-risk disease and to evaluate cell surface proteins targeted by emerging immunotherapies such as CAR T-cell therapies and bispecific antibodies. This dual assessment enables the stratification of patients based on genetic risk profiles and potential responsiveness to immunotherapies, paving the way for risk-adapted therapeutic regimens that optimize efficacy and minimize unnecessary toxicity.
The inception of JAYseq is underpinned by philanthropic dedication and collaborative vision. Named in memory of Jay Hollingsworth and made possible through the generosity of Susie Nason, the test draws upon the technological foundation laid by the ALTseq platform, itself a tribute to Robert Altman through the efforts of Lynda Carter Altman. Such partnerships underscore the transformative impact that sustained support and cross-disciplinary cooperation have on driving clinical innovation in cancer genomics.
Scientific leadership within TGen, including Dr. Jonathan Keats, has highlighted the crucial importance of accessing the full genomic blueprint of each myeloma tumor. This comprehensive insight not only identifies mutations that may predict therapy success but also unravels those that might be implicated in therapeutic resistance. Such granularity is indispensable for progressing beyond one-size-fits-all treatments towards truly bespoke therapeutic paradigms in oncology.
Despite the advent of multiple new therapeutic modalities, patient outcomes in multiple myeloma remain heterogeneous, underscoring an unmet need for tools that can decode the individual molecular contexts facilitating or hindering treatment efficacy. JAYseq satisfies this clinical imperative by providing a fast, all-encompassing genomic readout at critical junctures, such as initial diagnosis or disease relapse, enabling physicians to adapt treatment plans dynamically based on real-time molecular data.
Dr. Amrita Krishnan of City of Hope accentuates how JAYseq fills a critical void in precision treatment for multiple myeloma by delivering clarity and speed previously unattainable. With CAR T-cell therapies and bispecific antibodies revolutionizing the therapeutic landscape, integrating comprehensive genomic profiling into treatment algorithms is no longer optional but essential for driving optimal patient outcomes.
Patient advocacy organizations have often underscored the toll exacted by prolonged diagnostic uncertainty in multiple myeloma care journeys. The accelerated insights afforded by JAYseq alleviate this burden by shrinking the waiting period for definitive genomic information, thus empowering patients and clinicians alike with clearer, faster guidance. Moreover, this expedited access aligns seamlessly with the advocacy community’s goals of advancing precision medicine accessibility and patient empowerment.
Collaborative efforts between TGen and the Multiple Myeloma Research Foundation (MMRF) over the past 15 years have been integral to making whole-genome sequencing a clinical reality for multiple myeloma patients. Initiatives such as the MMRF’s Multiple Myeloma Research Consortium Genomics Initiative and the CoMMpass study have generated invaluable genomic datasets, propelling the understanding of the disease’s biology and establishing frameworks for personalized medicine approaches. These partnerships exemplify how shared data and expertise drive translational advancements benefiting the global myeloma community.
George Mulligan, Ph.D., chief scientific officer at MMRF, acknowledges the profound impact of this ongoing collaboration, citing the comprehensive genomic data accumulated through CoMMpass as a resource that continues to fuel innovation. With JAYseq’s launch, a new chapter in precision oncology begins, in which rapid whole-genome sequencing is poised to become a cornerstone of clinical decision-making for multiple myeloma patients.
Through the advent of JAYseq, TGen and City of Hope have entrusted clinicians with a powerful tool that unifies rapid, high-resolution genomic profiling with deep hematologic oncologic expertise. This fusion offers real promise for enhancing patient outcomes and ushering in a new era where treatment is precisely aligned with the unique genetic signatures defining each multiple myeloma tumor.
JAYseq is now accessible for clinical use through the TGen Clinical Laboratory, expanding availability of cutting-edge whole-genome sequencing for multiple myeloma patients and reinforcing TGen’s mission to accelerate genomic-driven personalized cancer care.
Subject of Research: Clinical whole-genome sequencing for multiple myeloma
Article Title: TGen Launches JAYseq™, a Rapid Whole-Genome Sequencing Test Revolutionizing Multiple Myeloma Diagnosis and Treatment
News Publication Date: Not specified
Web References:
https://www.tgen.org/
https://www.cityofhope.org/
https://www.tgen.org/service-centers/tgen-clinical-laboratory/jayseq/
Keywords: multiple myeloma, whole-genome sequencing, JAYseq, precision medicine, ALTseq technology, immunotherapy, CAR T-cell therapy, bi-specific antibodies, genomic profiling, cancer diagnostics, personalized treatment
Tags: 72-hour cancer diagnosis turnaroundadvanced cancer molecular mappingblood cancer genomic researchCity of Hope cancer diagnosticscomprehensive tumor genetic analysisgenomic alterations detection myelomaJAYseq clinical test innovationmultiple myeloma whole-genome sequencingpersonalized treatment strategies multiple myelomaprecision oncology diagnostic testrapid genomic profiling cancertranslational genomics clinical application
